Positive top-line results this week were announced from the multinational, pivotal Phase 3 SONICS study evaluating levoketoconazole for the treatment of endogenous Cushing’s syndrome. Strongbridge Biopharma is marketing the drug as RECORLEV™ . The open-label, single-arm SONICS study achieved statistical significance of its pre-specified primary endpoint, with 30 percent of patients achieving normalization of mean urinary...
Labconco SteamScrubber® 33 Now available in a new height of 33”, the SteamScrubber Glassware Washer fits beneath lower countertops. SteamScrubbers feature stainless steel top and bottom racks that accommodate basket inserts to hold a wide variety of glassware shapes and sizes, primarily beakers. Specialized inserts for petri dishes, culture tubes, and small utensils enhance the...
In Alexander Kauffman’s lab at UCSD, there are a few new fresh faces behind the goggles. His lab is recruiting high school students as interns to contribute “new perspectives and fearless solutions” to the traditional laboratory environment, not to mention inspiring a new generation of scientists. Look around the laboratory of Alexander (Sasha) Kauffman, PhD,...- Endocrine News
- Practice
- Diabetes Research Articles
- Products and Technological advancements in Endocrinology
ENDO 2018: Wearable Heart Rate Monitor Could Signal Low Blood Sugar in Type 1 Diabetes
A wearable medical patch measuring the beat-to-beat variation in heart rate is a promising device for the early detection of hypoglycemia, or low blood sugar, in type 1 diabetes, according to the researchers who tested the new monitor. Results of their preliminary study were presented Saturday at ENDO 2018, the Endocrine Society’s 100th annual meeting...
- Diabetes Research Articles
- Product / Technology
- Products and Technological advancements in Endocrinology
FDA Approves New Continuous Glucose Monitoring System with Predictive Algorithm Technology
The U.S. Food and Drug Administration (FDA) has approved a new continuous glucose monitoring (CGM) system for people with diabetes ages 14 to 75 years. Medtronic is marketing the system as Guardian Connect, the first smart standalone CGM system to help people with diabetes stay ahead of high and low glucose events. The Guardian Connect...
- Cardiometabolic
- Diabetes Research Articles
- Product / Technology
- Products and Technological advancements in Endocrinology
Late-breaking exploratory analysis from the CANVAS Program presented at the American College of Cardiology’s 67th Annual Scientific Session The results of recent analysis showed that canagliflozin significantly reduced the risk of cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) at high CV risk. This exploratory analysis from...
- Diabetes Research Articles
- Product / Technology
- Products and Technological advancements in Endocrinology
Reduced Time in Hypoglycemia Demonstrated in Recent Insulin Pump Trial
Positive results were announced this week from the study of a new insulin pump with a predictive low glucose suspend (PLGS) feature. Data showed that the system achieved the primary outcome of reducing time spent in hypoglycemia compared to sensor-augmented pump therapy alone. The company developing the device, Tandem Diabetes Care, is marketing its new...
FDA Approves Semaglutide Injection For the Treatment of Adults with Type 2 Diabetes
The U.S. Food and Drug Administration (FDA) approved semaglutidea once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The drug, produced by Novo Nordisk and marketed as OZEMPIC®, is administered once weekly, on the same day each week, and can be taken...
